Skip to Content

Separating from Johnson and Johnson and establishing a new biopharmaceutical business model has kept Steven Kasok, CFO, of Gallus BioPharmaceuticals very busy for the past year, as the company aspires to be “pure dead brilliant.”   Best known for the manufacture of Remicade and Stelara, two leading commercial biologics products, Gallus is working on attracting new customers and ensuring their business operations and models are best in class.  Offering a suite space virtual ownership model, Gallus provides customers with a segment of their facilities under its regulatory platform, while providing the customer flexible, decision making power over the manufacturing of their products.

Gallus focuses on its customer by delivering a faster, more cost effective process to get their drugs to market.  By taking care of the manufacturing from the early development stage; through clinical testing and ultimately into full commercial scale production, Gallus offers customers a manufacturing process they can trust. Their ultimate customer is a consumer who has a disease and needs a therapeutic medication, so it is vital that every process is well documented and transparent.

https://youtube.com/watch?v=P0RnzdcVHp0

Any new company faces many challenges, Kasok told SAP while at SAPPHIRE Now, “the cells didn’t know they were sold; the business needed to operate, so the functionality of SAP Business All in One fit the general parameters of what a company like us needed.” Keen to separate as quickly as possible from Johnson and Johnson systems, Gallus was running its own system within 14 weeks with no issues. When asked about choosing a hosted solution, Kasok remarked, “put the process of maintaining the IT infrastructure in the hands of the people who do that for a living—our job is growing cells. [The cloud] is part of our life–get comfortable with it.”

Customer Central Newsroom

To report this post you need to login first.

Be the first to leave a comment

You must be Logged on to comment or reply to a post.

Leave a Reply